Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
Launched by UNIVERSITY OF PITTSBURGH · Jun 18, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new mobile app designed to help people with schizophrenia and schizoaffective disorder manage their medications better. The goal is to see if using this app is practical and if people find it helpful. The researchers want to understand if the app can make it easier for patients to take their medications regularly, which is important for their mental health.
To participate in this study, individuals must be between the ages of 18 and 60 and have been diagnosed with schizophrenia or schizoaffective disorder, but they should be in a stable condition for at least two months. Participants should also be able to read and understand either Malayalam or English. However, those with ongoing symptoms, a history of substance use (besides nicotine), or serious physical health issues will not be eligible. If you join the trial, you can expect to use the app and provide feedback about your experience, which will help researchers understand how to improve mental health support for people with these conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Persons diagnosed with schizophrenia and schizoaffective disorder and are in remission for past two months.
- • 2. Age 18-60 years of any gender.
- • 3. Able to read and understand Malayalam/ English
- Exclusion Criteria:
- • 1. Patients who have active psychotic or mood symptoms.
- • 2. History of substance use (except nicotine)
- • 3. Having any serious physical illness. -
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palakkad, Kerala, India
Patients applied
Trial Officials
Vishwajit Nimgaonkar, MD, PhD
Principal Investigator
University of Pittburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported